Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 3 results

ea0026p225 | Pituitary | ECE2011

Effect of GH as add-on treatment in severe fibromyalgia syndrome. Results from the IIIb, CT27560 placebo-controlled, multicenter trial

Cuatrecasas Guillem , Alegre Cayetano , Sola Joaquim Fernandez , Gonzalez Maria Jose , Lage Mary , Sesmilo Gemma , Granados Enrique , Domingo Manuel Puig

Introduction: Functional GH deficiency has been described in fibromyalgia (FM). The efficacy of GH as add-on treatment has been suggested in small studies, but little is known in larger and homogeneous populations.Design: Patients (120) were enrolled in a multicenter, randomized, placebo-controlled trial for 18 months (NCT00933686). FM impact questionnaire (FIQ) >75 (severe), duration of FM >18 months, and stability of the standard therapy (amitr...
0 shares

ea0032p901 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Efficacy and safety of lanreotide in combination with pegvisomant in clinical practice in patients with active acromegaly with monotherapy failure

Venegas Eva , Lucas Tomas , Marazuela Monica , Cuatrecasas Guillem , Galvez Maria Angeles , Romero Enrique , Morales Francisco , Webb Susan M , Biaggeti Betina , Diaz Juan Jose , Mato Jose Antonio , Vilchez Ricardo , Bernabeu Ignacio , Paja Miguel , Pico Antonio , Domingo Manuel Puig , Soto Alfonso , on behalf of ACROCOMB study group

Introduction: ACROCOMB is a retrospective Spanish Multicenter study, designed to evaluate the efficacy (extent of tumour control) and safety of lanreotide (LAN) treatment combined with pegvisomant (PEG) or cabergoline in acromegalic patients with monotherapy failure.Methods: patients with acromegaly treated with LAN+PEG (45% of ACROCOMB patients) at 44 Spanish Endocrinology Departments were analysed.Results: 40% of patients were ma...
0 shares

ea0032p902 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Efficacy and safety of lanreotide in combination with cabergoline in clinical practice in patients with active acromegaly with monotherapy failure

Vilchez Ricardo , Bernabeu Ignacio , Blanco Concepcion , Cordido Fernando , Paja Miguel , Casany Rosa , Fajardo Carmen , Maraver Silvia , Martin Tomas , Lucas Tomas , Arnes Juan Antonio Garcia , Catalina Pablo Fernandez , Icaya Maria Purificacion Martinez de , Sesmilo Gemma , Pico Antonio , Marazuela Monica , Soto Alfonso , Domingo Manuel Puig , on behalf of ACROCOMB study group

Introduction: ACROCOMB, a retrospective Spanish Multicenter study, evaluated the efficacy and safety of lanreotide (LAN) combined with cabergoline (CAB), or pegvisomant in patients with acromegaly.Methods: patients treated with LAN+CAB at 44 Spanish Endocrinology Departments were included.Results: 33% male patients, median age: 50.4 years. Mean time from diagnosis: 5.9±6.9 years. Tumour size at diagnosis: 21.9 mm. 83% of patie...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more